Friess Associates’s Amedisys AMED Stock Holding History

Friess Associates’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-81,095	Closed	-$6.93M	–	118
2018 Q2	$6.93M	Buy	81,095 +33,495	+70%	+$2.46M	0.55%	64
2018 Q1	$2.87M	Buy	+47,600	New	+$2.71M	0.23%	86

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Friess Associates's AMED Position: Q3 2018 in Review

Friess Associates sold out of Amedisys (AMED) in Q3 2018, closing a stake of 81,095 shares — an estimated $6.93M sold.

Friess Associates first reported a position in AMED in Q1 2018 and held it in 2 quarters. The position peaked at $6.93M in Q2 2018. 265 funds tracked by Wall St. Rank hold AMED as of Q3 2018.

Friess Associates reported no remaining Amedisys position as of Q3 2018 after selling out during the quarter.
Friess Associates sold 81,095 Amedisys shares in Q3 2018, an estimated $6.93M.
Friess Associates first reported a position in Amedisys in Q1 2018 and held it in 2 quarters.
Friess Associates's Amedisys position peaked at $6.93M in Q2 2018.
265 funds tracked by Wall St. Rank held Amedisys as of Q3 2018.

Based on Friess Associates's 13F filing for Q3 2018, filed 14 Nov 2018.